2003•European Journal of Clinical PharmacologyRequires access

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

Gunnar Fager, Marie Cullberg, Maria Eriksson-Lepkowska, Lars Frison, Ulf G. Eriksson

Open publisher page 31 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 31 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ximelagatran, Direct thrombin inhibitor, Pharmacokinetics, Pharmacology, Chemistry, Prodrug, Oral administration, Discovery and development of direct thrombin inhibitors

Back to paper search Browse research topics Original source

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid — Research Paper | ScholarLens